Aurobindo Pharma has approved a proposal to amalgamate its step-down wholly owned subsidiaries, Eugia Steriles and Eugia SEZ, with Eugia Pharma Specialities, a wholly owned subsidiary of the company. The proposed Scheme of Amalgamation will be filed before the National Company Law Tribunal (NCLT), Hyderabad, following approval from the boards of all the respective companies.

Eugia Pharma Specialities, incorporated on April 17, 2013, will act as the transferee company under the proposed scheme. Eugia Steriles, incorporated on July 5, 2020, and Eugia SEZ, incorporated on February 20, 2021, will be merged into the entity as transferor companies.

According to the company, the restructuring is intended to simplify the existing corporate structure by consolidating entities engaged in substantially similar business activities into a single legal entity. The merger is expected to enhance operational efficiency by eliminating overlapping corporate and administrative functions while reducing associated overhead costs.

The consolidation is also expected to improve treasury management, optimise resource utilisation and generate operational synergies, enabling the company to strengthen its business operations and achieve greater cost efficiencies.

The proposed amalgamation forms part of Aurobindo Pharma's ongoing efforts to streamline its organisational structure and improve overall operational effectiveness across its Eugia business portfolio.